Deal Watch: BMS Looks To Molecular Templates’ Engineered Toxin Bodies In Cancer
Plus recent deals involving AbbVie/Caribou, Sanofi/i2O, Merck & Co./Starpharma, Protalix/SarcoMed, Targovax/Papyrus, Medivir/Ubiquigent, Eton/Azurity
You may also be interested in...
Sandoz has struck a deal worth up to $500m for GlaxoSmithKline’s cephalosporin antibiotics business, in a move that the Novartis subsidiary says will reinforce its leadership position in the field.
The company also raised a $70m Series A round and is looking to develop “off-the-shelf” gene therapies adapted to settings with fewer resources.
A new joint venture from Avacta and Daewoong Pharmaceutical aims to use novel mesenchymal stem cells to secrete antibody mimetic "Affimers" to treat inflammatory diseases.